These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 9296329)

  • 1. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general vs selected healthy subject populations.
    Chen S; Kumar S; Chou WH; Barrett JS; Wedlund PJ
    Br J Clin Pharmacol; 1997 Sep; 44(3):303-4. PubMed ID: 9296329
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytochrome P450 2D6 polymorphism and character traits.
    Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
    Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in the frequency of cytochrome P450-2D6 (CYP2D6) deficiency.
    Mörike K; Platten HP; Mikus G; Klotz U
    Br J Clin Pharmacol; 1998 Jul; 46(1):87. PubMed ID: 9690955
    [No Abstract]   [Full Text] [Related]  

  • 4. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
    Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
    Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
    Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
    Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
    Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
    Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C.
    Hijikata M; Miyakawa H; Matsushita M; Kako M; Ohta Y; Mishiro S
    Biochem Biophys Res Commun; 2000 Apr; 270(3):922-6. PubMed ID: 10772926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
    Buzková H; Pechandová K; Slanar O; Perlík F
    Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
    McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 CYP2D6.
    Wolf CR; Smith G
    IARC Sci Publ; 1999; (148):209-29. PubMed ID: 10493260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms of CYP2D6 in Chinese mainland.
    Ji L; Pan S; Wu J; Marti-Jaun J; Hersberger M
    Chin Med J (Engl); 2002 Dec; 115(12):1780-4. PubMed ID: 12622923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
    Ingelman-Sundberg M
    Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
    Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
    Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
    Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
    Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cytochrome P450 2D6 alleles using the Invader system.
    Nevilie M; Selzer R; Aizenstein B; Maguire M; Hogan K; Walton R; Welsh K; Neri B; de Arruda M
    Biotechniques; 2002 Jun; Suppl():34-8, 40-3. PubMed ID: 12083395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
    Nikoloff D; Shim JC; Fairchild M; Patten N; Fijal BA; Koch WH; MacPherson A; Flockhart D; Yoon YR; Yoon JS; Kim YH; Shin JG
    Pharmacogenomics J; 2002; 2(6):400-7. PubMed ID: 12629505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
    Yu A; Kneller BM; Rettie AE; Haining RL
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
    Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
    Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.